BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Mok WC, Wasser S, Tan T, Lim SG. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J Gastroenterol 2012; 18(27): 3527-3536 [PMID: 22826617 DOI: 10.3748/wjg.v18.i27.3527]
URL: https://www.wjgnet.com/1007-9327/full/v18/i27/3527.htm
Number Citing Articles
1
Peter Dietrich, Kim Freese, Abdo Mahli, Wolfgang Erwin Thasler, Claus Hellerbrand, Anja Katrin Bosserhoff. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” optionOncotarget 2018; 9(3) doi: 10.18632/oncotarget.23188
2
Luc Magloire Anicet Boumba, Clausina Ahoui Mikolele, Dimitri Moudiongui Mboungou Malanda, Ghislain Lobano-Voumbi, Bredin Bissila, Josué Lukera Chimaëlle Biziki Batsimba, Paola Candyse Tsimba, Blaise Irenée Atipo Ibara, Donatien Moukassa. Impact of the Hepatitis B Virus pRE-S2 Mutant on p53 and PLK1 Biomarkers Expression in Patients with Hepatocellular Carcinoma in BrazzavilleAdvances in Infectious Diseases 2025; 15(04) doi: 10.4236/aid.2025.154052
3
Ya-Hui Huang, Ying-Hsin Tseng, Wey-Ran Lin, George Hung, Tse-Ching Chen, Tong-Hong Wang, Wei-Chen Lee, Chau-Ting Yeh. HBV polymerase overexpression due to large core gene deletion enhances hepatoma cell growth by binding inhibition of microRNA-100Oncotarget 2016; 7(8) doi: 10.18632/oncotarget.7021
4
Rodrigo F.E. Bogado, Julia A. Pezuk, Harley F. de Oliveira, Luiz G. Tone, María S. Brassesco. BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatmentsAnti-Cancer Drugs 2015; 26(1) doi: 10.1097/CAD.0000000000000157
5
Jean Baptiste Gossart, Etienne Pascal, Florent Meyer, Emilie Heuillard, Mathieu Gonçalves, Francine Gossé, Eric Robinet, Benoît Frisch, Cendrine Seguin, Guy Zuber. Performance of Pyridylthiourea‐Polyethylenimine Polyplex for siRNA‐Mediated Liver Cancer Therapy in Cell Monolayer, Spheroid, and Tumor Xenograft ModelsGlobal Challenges 2017; 1(4) doi: 10.1002/gch2.201700013
6
Imane El Dika, Ho Yeong Lim, Wei Peng Yong, Chia-Chi Lin, Jung-Hwan Yoon, Manuel Modiano, Bradley Freilich, Hye Jin Choi, Tsu-Yi Chao, Robin K. Kelley, Joanne Brown, Jennifer Knox, Baek-Yeol Ryoo, Thomas Yau, Ghassan K. Abou-Alfa. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular CarcinomaThe Oncologist 2019; 24(6) doi: 10.1634/theoncologist.2018-0838
7
Xia-Qing Zhou, Ya-Ping Li, Shuang-Suo Dang. Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapyWorld Journal of Hepatology 2024; 16(2): 164-176 doi: 10.4254/wjh.v16.i2.164
8
Kuo-Shyang Jeng, Chiung-Fang Chang, Wen-Juei Jeng, I-Shyan Sheen, Chi-Juei Jeng. Heterogeneity of hepatocellular carcinoma contributes to cancer progressionCritical Reviews in Oncology/Hematology 2015; 94(3) doi: 10.1016/j.critrevonc.2015.01.009
9
Mohan Liu, Yusi Wang, Yibing Zhang, Die Hu, Lin Tang, Bailing Zhou, Li Yang. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicinesSignal Transduction and Targeted Therapy 2025; 10(1) doi: 10.1038/s41392-024-02112-8
10
Zhixian Liu, Qingrong Sun, Xiaosheng Wang. PLK1, A Potential Target for Cancer TherapyTranslational Oncology 2017; 10(1) doi: 10.1016/j.tranon.2016.10.003
11
Sophie Cazanave, Alexei Podtelezhnikov, Kristian Jensen, Mulugeta Seneshaw, Divya P. Kumar, Hae-Ki Min, Prasanna K. Santhekadur, Bubu Banini, Adolfo Gabriele Mauro, Abdul M. Oseini, Robert Vincent, Keith Q. Tanis, Andrea L. Webber, Liangsu Wang, Pierre Bedossa, Faridoddin Mirshahi, Arun J. Sanyal. The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver DiseaseScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-17370-6
12
Sara Ortica, Nadine Tarantino, Nathalie Aulner, Alain Israël, Neetu Gupta‐Rossi. The 4 Notch receptors play distinct and antagonistic roles in the proliferation and hepatocytic differentiation of liver progenitorsThe FASEB Journal 2014; 28(2) doi: 10.1096/fj.13-235903
13
Soham Bhattacharyya, Debopriya Choudhury, Brahmachari Vedeshachaitanya, Pushkar Malakar. Cell FusionAdvances in Experimental Medicine and Biology 2026; 1509 doi: 10.1007/978-3-032-22637-2_10
14
Zheng Fu, Donghua Wen. The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisCancers 2017; 9(10) doi: 10.3390/cancers9100131
15
Michael M.C. Lai, Wen‐Chi Su. Polo‐like‐kinase 1: A key cellular target for anti‐HBV therapy?Hepatology 2017; 66(6) doi: 10.1002/hep.29407
16
Julia Alejandra Pezuk, María Sol Brassesco, Andressa Gois Morales, Jaqueline Carvalho de Oliveira, Harley Francisco de Oliveira, Carlos Alberto Scrideli, Luiz Gonzaga Tone. Inhibition of Polo-Like Kinase 1 Induces Cell Cycle Arrest and Sensitizes Glioblastoma Cells to Ionizing RadiationCancer Biotherapy and Radiopharmaceuticals 2013; 28(7) doi: 10.1089/cbr.2012.1415
17
Shufeng Wang, Xinzheng Wang, Xin Yang, Feng Liu, Jin Li, Weihua Li, Zhaofang Bai, Hongbo Wang, Jie Mao, Tingting Li, Kun He, Hongxia Wang. Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissuesPROTEOMICS 2022; 22(4) doi: 10.1002/pmic.202100141
18
Yingai Zhang, Shunlan Wang, Jingchuan Xiao, Hailong Zhou. Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinomaBioscience Reports 2019; 39(2) doi: 10.1042/BSR20181845
19
Chelsea E. Cunningham, Mackenzie J. MacAuley, Frederick S. Vizeacoumar, Omar Abuhussein, Andrew Freywald, Franco J. Vizeacoumar. The CINs of Polo-Like Kinase 1 in CancerCancers 2020; 12(10) doi: 10.3390/cancers12102953
20
Ariel Ka-Man Chow, Simon Wing-Lung Yau, Lui Ng. Novel molecular targets in hepatocellular carcinomaWorld Journal of Clinical Oncology 2020; 11(8): 589-605 doi: 10.5306/wjco.v11.i8.589
21
Mahmoud A. Younis, Ikramy A. Khalil, Hideyoshi Harashima. Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical ApplicationsAdvanced Therapeutics 2020; 3(11) doi: 10.1002/adtp.202000087
22
Mahmoud Younis, Hideyoshi Harashima. Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized MedicinePharmacogenomics and Personalized Medicine 2024;  doi: 10.2147/PGPM.S431346
23
Bin Shi, Marc Abrams, Laura Sepp-Lorenzino. Expression of Asialoglycoprotein Receptor 1 in Human Hepatocellular CarcinomaJournal of Histochemistry & Cytochemistry 2013; 61(12) doi: 10.1369/0022155413503662
24
Hongjun Yu, Chaoqun Wang, Shanjia Ke, Miaoyu Bai, Yanan Xu, Shounan Lu, Zhigang Feng, Baolin Qian, Yue Xu, Menghua Zhou, Zihao Li, Bing Yin, Xinglong Li, Yongliang Hua, Yongzhi Zhou, Shangha Pan, Yao Fu, Yong Ma. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular CarcinomaFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.892750
25
Yeonhwa Song, Su-Yeon Lee, Sanghwa Kim, Inhee Choi, Namjeong Kim, Jongmin Park, Haeng Ran Seo. HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular CarcinomaCancers 2023; 15(3) doi: 10.3390/cancers15030851
26
Zewen Song, Zhaomei Yu, Limin Chen, Zhijiao Zhou, Qiong Zou, Yang Liu. MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1Biomedicine & Pharmacotherapy 2019; 119 doi: 10.1016/j.biopha.2019.109397